Cas no 64485-93-4 (Cefotaxime sodium)
Cefotaxime sodium Chemical and Physical Properties
Names and Identifiers
-
- Cefotaxime sodium
- Ce-fotax
- Chemcef
- Claforan
- Pretor
- Tolycar[6R-[6alpha,7beta(z)]]-3-[(Acetyloxy)methyl]-[[(2-amine-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid monosodium salt
- CTX
- Cefotaxim sodium salt
- Cefotaxime (sodium salt)
- Cefotaxime sodium salt
- Cefotax
- Cefotaxime Na
- Cyclopentyl Methyl ether
- FIR-756
- hr756
- sodium cefotaxime
- Tolycar
- [6R-[6alpha,7beta(z)]]-3-[(Acetyloxy)methyl]-[[(2-amine-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid monosodium salt
- CEFOTAXIME NA-SALT
- cefotaxime-sodium
- DSSTox_CID_26991
- DSSTox_RID_82039
- DSSTox_GSID_46991
- SPECTRUM1500165
- HMS502G09
- AZZMGZXNTDTSME-JUZDKLSSSA-M
- HMS1920K09
- HMS2091A12
- Tox21_110791
- AB03027
- LP00278
- TL8004572
- sodium (6R,7R)-3-[(acetyloxy)methyl]-7-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene
- Sodium;(6R,7R)-3-(acetyloxymethyl)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]
- HR-756 sodium salt
- CEFOTAXIME SODIUM [MART.]
- CEFOTAXIME SODIUM [VANDF]
- HMS3260H18
- CEFOTAXIME SODIUM [EP IMPURITY]
- D00919
- CEFOTAXIME SODIUM (MART.)
- HR 756
- Ralopar
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-(acetyloxy)methyl-7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo, monosodium salt, [6R-[6alpha,7 beta (Z)]]-
- CEFOTAXIME SODIUM [USP MONOGRAPH]
- Cefotaxime and dextrose 3.9% in plastic container
- Sodium, Cefotaxime
- sodium;(6R,7R)-3-(acetyloxymethyl)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- UNII-258J72S7TZ
- CEFOTAXIME SODIUM [WHO-DD]
- HR-756
- CAS-64485-93-4
- C2224
- EN300-25953723
- Sodium (6R-(6alpha,7beta(Z)))-3-(acetoxymethyl)-7-((2-aminothiazol-4-yl)(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
- C 7912
- NSC-756666
- Claforan (TN)
- CEFOTAXIME SODIUM (USP IMPURITY)
- CEFOTAXIME SODIUM (EP IMPURITY)
- Sym-methoxyimino Cephalosporin
- 64485-93-4
- Sodium 7-(2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)cephalosporanate
- cefotaxime
- CHEBI:3498
- sodium 3-(acetoxymethyl)-7beta-(((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3,4-didehydrocepham-4-carboxylate
- CHEMBL1010
- MLS000028559
- Monosodium (6R,7R)-3-acetoxymethyl-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetylamino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
- DTXCID201476109
- DTXSID4046991
- NCGC00093734-02
- MLS002222330
- CEFOTAXIME SODIUM [JAN]
- Cefotaxime and dextrose 2.4% in plastic container
- sodium (6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefotaxime sodium [USAN:USP:JAN]
- NCGC00093734-01
- NCGC00017128-01
- Cefotaxime for peak identification, European Pharmacopoeia (EP) Reference Standard
- SMR000058812
- Zariviz
- AKOS015951272
- SMR000653480
- Cefotaxime (sodium)
- CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- EINECS 264-915-9
- sodium (6R,7R)-3-(acetoxymethyl)-7-(((2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
- CEFOTAXIME SODIUM [ORANGE BOOK]
- CCG-220139
- CCG-221582
- MLS001077352
- Cefotaxime sodium salt, potency: 916-964 mug per mg
- MFCD00079073
- 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt, (6R-(6alpha,7beta(Z)))-
- Ru-24756
- Cefotaxime sodium, United States Pharmacopeia (USP) Reference Standard
- 258J72S7TZ
- NSC 756666
- Cefotaxime sodium (USAN:USP:JAN)
- SMR001307269
- C08113
- Q-200807
- Cefadroxil, Antibiotic for Culture Media Use Only
- AMY40166
- CEFOTAXIME SODIUM (USP MONOGRAPH)
- Cefotaxim sodium
- CEFOTAXIME SODIUM (USP-RS)
- Tolycor
- KS-1416
- RU 24756
- CEFOTAXIME SODIUM [USP IMPURITY]
- Tox21_500278
- CEFOTAXIME SODIUM [USP-RS]
- s4517
- CEFOTAXIME SODIUM SALT [MI]
- CS-4297
- HMS1568K20
- SCHEMBL41092
- cefotaxime injection
- EU-0100278
- 5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-((ACETYLOXY)METHYL)-7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-8-OXO-, MONOSODIUM SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-
- Sodium (6R,7R)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 7[2]-(Z)-(O-methyloxime), acetate (ester)
- HMS3712K20
- Cefotaxime sodium salt, plant cell culture tested, BioReagent, powder
- HMS2233J21
- SODIUM (6R,7R)-3-(ACETOXYMETHYL)-7-((E)-2-(2-AMINOTHIAZOL-4-YL)-2-(METHOXYIMINO)ACETAMIDO)-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLATE
- Opera_ID_1945
- HMS2095K20
- Cefotaxime sodium salt (syn-isomer)
- sodium;(6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- NCGC00260963-01
- MLS001333684
- sodium 3-(acetoxymethyl)-7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3,4-didehydrocepham-4-carboxylate
- Cefotaxime sodium, European Pharmacopoeia (EP) Reference Standard
- 63527-52-6 (acid)
- Sodium (6R,7R)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate 7(sup 2)-(Z)-(O-methyloxime), acetate (ester)
- (+)-Cefotaxime sodium salt
- Claforan sodium
- CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
- Cefotaxime sodium (JP17/USP)
- sodium (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- HY-A0088
- Prestwick_823
- CEFOTAXIME SODIUM [USAN]
- Cefotaxime sodium (JP18/USP)
- inverted exclamation markY99.5% pound HPLC)
-
- MDL： MFCD00079073
- Inchi： 1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1
- InChI Key： AZZMGZXNTDTSME-JUZDKLSSSA-M
- SMILES： S1CC(COC(C)=O)=C(C(=O)[O-])N2C([C@H]([C@@H]12)NC(/C(/C1=CSC(N)=N1)=N\OC)=O)=O.[Na+]
Computed Properties
- Exact Mass: 477.03900
- Monoisotopic Mass: 477.039
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 12
- Heavy Atom Count: 31
- Rotatable Bond Count: 8
- Complexity: 839
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 1
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 230
- Surface Charge: 0
Experimental Properties
- Color/Form: Powder
- Density: 1.8000
- Melting Point: 201-210°C
- Boiling Point: No data available
- Flash Point: No data available
- Refractive Index: 61 ° (C=1, H2O)
- Solubility: H2O: aqueous solutions of pH 4.3-6.2 are stable up to 3 weeks at 2-8 °C.soluble
- Water Partition Coefficient: Soluble in water.
- Stability/Shelf Life: Stable. Incompatible with strong oxidizing agents.
- PSA: 229.88000
- LogP: -1.04720
- Merck: 14,1933
- Specific Rotation: +58.0° +65° (c=1, H2O)
- Solubility: Soluble in water, slightly soluble in ethanol, insoluble in chloroform.
- Vapor Pressure: No data available
Cefotaxime sodium Security Information
-
Symbol:
- Signal Word：Danger
- Hazard Statement： H317,H334
- Warning Statement： P261,P280,P342+P311
- WGK Germany：2
- Hazard Category Code： R42/43: inhalation and skin contact can cause allergy.
- Safety Instruction： S22-S36-S37
- RTECS：XI0250000
-
Hazardous Material Identification：
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- HazardClass：6.1
- PackingGroup：Ⅲ
- Risk Phrases：R42/43
Cefotaxime sodium Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd. | BBP80348-5mg |
Cefotaxime sodium |
64485-93-4 | 98.0% | 5mg |
￥100 | 2021-05-07 | |
| MedChemExpress | HY-A0088-10mM*1mLinDMSO |
Cefotaxime sodium |
64485-93-4 | 99.66% | 10mM*1mLinDMSO |
￥550 | 2022-05-18 | |
| MedChemExpress | HY-A0088-100mg |
Cefotaxime sodium |
64485-93-4 | 99.25% | 100mg |
￥500 | 2024-04-18 | |
| MedChemExpress | HY-A0088-250mg |
Cefotaxime sodium |
64485-93-4 | 99.25% | 250mg |
￥1000 | 2024-04-18 | |
| MedChemExpress | HY-A0088-500mg |
Cefotaxime sodium |
64485-93-4 | 99.25% | 500mg |
￥1350 | 2024-04-18 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C102193-5g |
Cefotaxime sodium |
64485-93-4 | ≥99.5%（HPLC) | 5g |
￥257.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C102193-250mg |
Cefotaxime sodium |
64485-93-4 | ≥99.5%（HPLC) | 250mg |
￥61.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C102193-100g |
Cefotaxime sodium |
64485-93-4 | ≥99.5%（HPLC) | 100g |
￥2956.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C102193-50mg |
Cefotaxime sodium |
64485-93-4 | ≥99.5%（HPLC) | 50mg |
￥41.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C102193-25g |
Cefotaxime sodium |
64485-93-4 | ≥99.5%（HPLC) | 25g |
￥1029.90 | 2023-09-04 |
Cefotaxime sodium Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Cefotaxime sodium Related Literature
-
Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
-
Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
-
Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
Additional information on Cefotaxime sodium
Cefotaxime Sodium: A Comprehensive Overview
Cefotaxime sodium, with the CAS number 64485-93-4, is a third-generation cephalosporin antibiotic that has been widely used in clinical settings for the treatment of various bacterial infections. This compound belongs to the broader class of beta-lactam antibiotics, which are known for their ability to inhibit bacterial cell wall synthesis. Cefotaxime sodium is particularly effective against a wide range of gram-positive and gram-negative bacteria, making it a valuable tool in the fight against antibiotic resistance.
The chemical structure of cefotaxime sodium includes a beta-lactam ring fused to a dihydrothiazine ring, which contributes to its broad-spectrum activity. This structure allows it to effectively bind to penicillin-binding proteins (PBPs) in bacterial cells, leading to cell wall disruption and bacterial death. Recent studies have highlighted the importance of understanding the molecular mechanisms behind cefotaxime's activity, particularly in light of increasing antibiotic resistance. Researchers have explored the role of efflux pumps and beta-lactamase enzymes in reducing cefotaxime's efficacy, providing insights into potential strategies to combat resistance.
In terms of pharmacokinetics, cefotaxime sodium is typically administered intravenously or intramuscularly, with rapid absorption and distribution throughout the body. Its elimination half-life is relatively short, allowing for frequent dosing schedules. However, recent research has focused on developing extended-release formulations to improve patient compliance and reduce the risk of resistance. These formulations aim to maintain therapeutic drug concentrations over an extended period, potentially enhancing treatment outcomes.
Clinically, cefotaxime sodium is often used as a first-line therapy for infections such as urinary tract infections, respiratory tract infections, and meningitis. Its ability to penetrate into cerebrospinal fluid makes it particularly useful in treating central nervous system infections caused by susceptible bacteria. Recent studies have also explored its efficacy in treating infections caused by multi-drug resistant organisms (MDROs), such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE). While cefotaxime sodium remains effective against many pathogens, its use must be guided by local resistance patterns and susceptibility testing.
One area of active research involves the combination of cefotaxime sodium with beta-lactamase inhibitors to enhance its activity against resistant bacteria. For example, the combination of cefotaxime with clavulanic acid has shown promise in overcoming resistance mechanisms mediated by extended-spectrum beta-lactamases (ESBLs). This approach not only restores cefotaxime's efficacy but also broadens its spectrum of activity against challenging pathogens.
Another important aspect of cefotaxime sodium's profile is its safety and tolerability. While generally well-tolerated, it can cause adverse effects such as gastrointestinal disturbances, allergic reactions, and nephrotoxicity in certain patient populations. Recent studies have focused on identifying risk factors for these adverse events and developing strategies to minimize their occurrence. For instance, dose adjustment based on renal function has been shown to reduce the risk of nephrotoxicity in elderly patients or those with pre-existing kidney disease.
Looking ahead, the role of cefotaxime sodium in antimicrobial stewardship programs is increasingly being recognized. These programs aim to optimize antibiotic use through education, monitoring, and feedback mechanisms. By promoting appropriate prescribing practices and reducing unnecessary use, antimicrobial stewardship can help preserve the effectiveness of cefotaxime sodium and other antibiotics against emerging resistant pathogens.
In conclusion, cefotaxime sodium remains a cornerstone in the treatment of bacterial infections due to its broad spectrum of activity and favorable pharmacokinetic profile. However, its continued effectiveness depends on addressing challenges such as antibiotic resistance and optimizing its use through evidence-based practices. Ongoing research into new formulations, combination therapies, and stewardship strategies will be critical in ensuring that cefotaxime sodium continues to play a vital role in combating bacterial infections worldwide.
